182 related articles for article (PubMed ID: 37585673)
1. Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review.
Zhang L; Wang L; Cheng Q; Lei X; Wu J; Chen N
Immunotherapy; 2023 Oct; 15(15):1249-1256. PubMed ID: 37585673
[TBL] [Abstract][Full Text] [Related]
2. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review.
Yang W; Xu X; Xia D; Wang H; Jiang J; Yang G
Immunotherapy; 2022 Apr; 14(5):275-282. PubMed ID: 35128931
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
4. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
Emonet C; Tétart F; Bauvin O; Cellier L; Courville P; Mignard C; Janela-Lapert R; Lefebvre A; Lachkar S; Lechevalier D; Lagarce L; Carvalho P; Tedbirt B
J Immunother; 2023 Feb-Mar 01; 46(2):59-63. PubMed ID: 36622668
[TBL] [Abstract][Full Text] [Related]
5. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
6. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report.
Li G; Gong S; Wang N; Yao X
Front Immunol; 2022; 13():989966. PubMed ID: 36090976
[TBL] [Abstract][Full Text] [Related]
7. Lichenoid dermatitis preceding Stevens-Johnson syndrome in a patient treated with nivolumab.
Potts J; Lee RR; Hilliard CA
BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 36028237
[TBL] [Abstract][Full Text] [Related]
8. Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report.
Jiang Z; Chen X; Sun Z; Shen X; Huang Y; Liu J
J Inflamm Res; 2023; 16():5061-5067. PubMed ID: 37936597
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Stevens Johnson - Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients.
Alexandris D; Alevizopoulos N; Gakiopoulou H; Stavrinou N; Vourlakou C
J Oncol Pharm Pract; 2022 Jul; 28(5):1276-1282. PubMed ID: 35038934
[TBL] [Abstract][Full Text] [Related]
10. A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma.
Gong Y; Mao J; Liu M; Gao J
J Int Med Res; 2023 May; 51(5):3000605231173556. PubMed ID: 37211771
[TBL] [Abstract][Full Text] [Related]
11. Toxic epidermal necrolysis associated with pembrolizumab.
Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature.
Sato I; Mizuno H; Kataoka N; Kunimatsu Y; Tachibana Y; Sugimoto T; Tani N; Ogura Y; Hirose K; Takeda T
Medicina (Kaunas); 2020 Aug; 56(8):. PubMed ID: 32796633
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.
Gallo Marin B; Oliva R; Kahn B; Borgovan T; Brooks BE; Massoud CM
R I Med J (2013); 2022 Apr; 105(3):34-36. PubMed ID: 35349618
[TBL] [Abstract][Full Text] [Related]
14. Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review.
Logan IT; Zaman S; Hussein L; Perrett CM
J Immunother; 2020 Apr; 43(3):89-92. PubMed ID: 31651559
[TBL] [Abstract][Full Text] [Related]
15. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review.
Zhang L; Wu Z
Clin Cosmet Investig Dermatol; 2023; 16():457-461. PubMed ID: 36846442
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma.
Yang H; Ma Q; Sun Y; Zhang K; Xing Y; Li H
Front Oncol; 2022; 12():1065137. PubMed ID: 36620577
[TBL] [Abstract][Full Text] [Related]
18. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
[TBL] [Abstract][Full Text] [Related]
19. Treatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: A Case Report and Brief Review.
Zhao Y; Cao Y; Wang X; Qian T
Onco Targets Ther; 2022; 15():345-351. PubMed ID: 35422628
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management.
Pach J; Leventhal JS
Crit Rev Immunol; 2022; 42(4):1-20. PubMed ID: 37022356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
